Balthaser Kevin
SEC CIK 1957554 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | CFO | 187.5K | $75.0K | $23.6K | 25 | 2023-03-01 | 2026-03-01 |
Most active insiders at ACRS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Leonard Braden Michael | 10% | — | $1.36M |
| 2 | Kolbeck Roland Wilhelm | CSO | — | — |
| 3 | Hall Jesse Wayne | Chief Medical Off | — | — |
| 4 | Davis Hugh M. | Pres, COO, Dir | — | — |
| 5 | Balthaser Kevin | CFO | — | — |
| 6 | Loerop James | Chief Business Off | — | — |
| 7 | Humphries William D. | Dir | — | — |
| 8 | Molineaux Christopher P. | Dir | — | — |
| 9 | Walker Neal | CEO, Dir | — | — |
| 10 | Mehra Anand | Dir | — | — |
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-03-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $2.87 | -677 | 187.5K | -0.4% | -$1,943 |
| D | 2026-03-03 | 2026-03-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +2,375 | 188.1K | +1% | — |
| D | 2026-02-05 | 2026-02-03 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +22.0K | 192.2K | +13% | — |
| D | 2026-02-05 | 2026-02-03 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $3.47 | -6,449 | 185.8K | -3% | -$22.4K |
| D | 2026-02-03 | 2026-02-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $3.51 | -4,984 | 170.2K | -3% | -$17.5K |
| D | 2026-02-03 | 2026-02-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +14.8K | 175.2K | +9% | — |
| DM | 2026-01-05 | 2025-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $2.99 | -26.6K | 146.4K | -15% | -$79.6K |
| DM | 2026-01-05 | 2025-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +94.5K | 153.9K | +159% | — |
| D | 2025-03-04 | 2025-03-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $1.99 | -727 | 92.6K | -0.8% | -$1,447 |
| DM | 2025-03-04 | 2025-03-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +3,475 | 91.0K | +4% | — |
| D | 2025-02-04 | 2025-02-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $2.48 | -5,816 | 89.9K | -6% | -$14.4K |
| D | 2025-02-04 | 2025-02-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +14.8K | 95.7K | +18% | — |
| DM | 2025-01-03 | 2024-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $2.48 | -38.2K | 80.9K | -32% | -$94.8K |
| DM | 2025-01-03 | 2024-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +94.5K | 86.0K | New | — |
| D | 2024-09-04 | 2024-09-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +1,000 | 25.0K | +4% | — |
| D | 2024-09-04 | 2024-09-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $1.18 | -286 | 24.7K | -1% | -$337.48 |
| DM | 2024-03-05 | 2024-03-01+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +4,975 | 24.4K | +26% | — |
| DM | 2024-03-05 | 2024-03-01+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $1.24 | -1,417 | 24.0K | -6% | -$1,757 |
| D | 2024-01-03 | 2024-01-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $1.05 | -2,536 | 20.4K | -11% | -$2,663 |
| D | 2024-01-03 | 2024-01-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +7,500 | 23.0K | +49% | — |
| 2023-09-07 | 2023-09-06 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | P - Purchase | $7.90 | +9,490 | 15.5K | +159% | +$75.0K | |
| D | 2023-09-05 | 2023-09-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | F - Tax | $7.90 | -285 | 5,971 | -5% | -$2,252 |
| D | 2023-09-05 | 2023-09-01 | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +1,000 | 6,256 | +19% | — |
| DM | 2023-03-03 | 2023-03-01+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | M - OptEx | — | +6,450 | 5,650 | New | — |
| DM | 2023-03-03 | 2023-03-02+ | ACRS | Aclaris Therapeutics, Inc. | Balthaser Kevin | CFO | S - Sale+OE | $12.45 | -1,894 | 4,650 | -29% | -$23.6K |
Purchase Sale Sale after option exercise All abbreviations